The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- LDP Policy Statement Calls for Perpetuation of New Drug Premium, Promotion of Switch-OTC Drugs
November 26, 2012
- MHLW Approves Additional Indications for 3 APIs/5 Products, Including Botox
November 26, 2012
- Even Non-Welfare Beneficiaries Have No Obligation to Use of Generics: Health Minister Mitsui
November 22, 2012
- MHLW Set to Clarify Review Procedures for Companion Diagnostics
November 21, 2012
- Translational Research, Biobank Projects Require Drastic Revision: Project Screening
November 21, 2012
- PAFSC’s 2nd Committee to Review 7th Biopharmaceutical RA Drug on Nov. 29
November 20, 2012
- PAFSC’s 1st Committee to Review 7 Products Including BMKK’s Apixaban on Nov. 30
November 20, 2012
- Re-Pricing of Generic Drugs Added to GRU’s Recommendation: Project Screening
November 20, 2012
- GRU to Propose that Welfare Beneficiaries Be Required to Use Generics as a Rule
November 20, 2012
- Temporary Halts in Generic Product Marketing, JGA Accelerates Efforts in Collecting Information
November 19, 2012
- Average Foreign Price Adjustment Results in NHI Price Lower than Manufacturing Cost for Pfizer Japan’s Tygacil: CSIMC
November 16, 2012
- CSIMC Subcommittee Eyes Price Cuts for Long-Listed Drugs with Slow Generic Penetration
November 16, 2012
- CSIMC OKs Listing for 15 APIs/22 Products; Peak Sales Estimated at 32.6 Billion Yen for Lotriga
November 15, 2012
- MHLW Director Suggests Being Ready for Increased Official Management if 3rd Round of Distribution Reform Fails
November 14, 2012
- Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
- Hodanren Asks MHLW to Disclose Discussions by Members of Drug Pricing Organization
November 13, 2012
- Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
- Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
- 15 Pharmacies Wrongly Claimed 41.6 Million Yen in Dispensing Fees Over 6 Year Period: Board of Audit
November 7, 2012
- Kampo Should Be Excluded from Denominator to Figure out Generic Volume Share
November 5, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…